| The Cancer Risk for Purebred Dogs Numerous research projects are under way to try to identify genes that predispose purebred dogs to cancer. In the meantime, lifestyle choices can help reduce their risk. online.wsj.com |
Spherix Expands Development Strategy for D-Tagatose (PR Newswire) Spherix Incorporated , an innovator in biotechnology for diabetes therapy, and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today announced that it will explore triglycerides as a potential therapeutic opportunity for its D-tagatose therapy, pending a review of data from a Phase 3 clinical trial the Company is conducting on the use of D-tagatose as a treatment for Type 2 diabetes. Â Reduction of triglyceride levels is a secondary endpoint of the Phase 3 trial. Â Results from the trial are expected later this summer. us.rd.yahoo.com |
Baxter's Profit Drops 8.9% Baxter International's second-quarter earnings fell 8.9%, including a charge, as it faced macroeconomic headwinds and individual product issues. online.wsj.com |
RadNet Enters the Radiology Software Business: Acquires eRAD, Inc. and Assembles an Industry-Leading Radiology Software Team [GlobeNewswire] - LOS ANGELES -- RadNet, Inc. , a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 191 fully-owned and operated outpatient imaging centers, today reported it has executed a definitive agreement to acquire Image Medical Corporation, the parent of eRAD, Inc., for $10.75 million in a combination of cash and promissory notes. us.rd.yahoo.com |
Glaxo Meets Big Disappointment in Failed Herpes Vaccine Pharmalot submits: An effort that began eight years ago to develop a herpes simplex vaccine for women has ended in failure and uncertainty. After assessing final Phase III trial results, the GlaxoSmithKline (GSK) vaccine, known as Simplirix, failed to meet its primary endpoint, which was preventing genital herpes. However, it remains unclear why the vaccine was not effective. Safety issues were not cited as a problem. The outcome is a huge disappointment for the drugmaker, which has been attempting to expand its portfolio of vaccine products, given that an estimated one in four women in the US alone has genital herpes. In other words, the afflication is one of the most common infectious diseases and that can translate into huge revenues.Complete Story » seekingalpha.com |